Leading Russian and foreign drug manufacturers operating in the local market have warned the national government about the forthcoming rise in prices that will come about as a result of certain innovations introduced by the Russian government in the national pharmaceutical industry. 16 July 2018
Andrew Rut, chief executive of MyMeds&Me, writes an Expert View piece on Japanese openings for tech-based pharmacovigilance firms in the wake of regulatory changes. 12 July 2018
Like other victims of a toxic US political environment, Obama-era FDA pick Robert Califf did not long survive the political turbulence of presidential election season. 11 July 2018
As a movie on anti cancer medication smuggled from India rakes in big bucks across China, the two countries have reached an agreement and have initiated specific measures for the import of Indian pharmaceuticals, especially anti-cancer drugs, reports The Pharma Letter’s India correspondent. 11 July 2018
In March 2018, Celgene announced its intention to co-develop and co-market bb2121, a bluebird bio CAR-T cell therapy for relapsed multiple myeloma. In conversation with The Pharma Letter, Tuomo Pätsi, worldwide president for hematology and oncology markets, makes a strong case for the drug. 11 July 2018
A small Swedish pharmaceutical company has taken another step towards being the first company in the world to launch a targeted treatment for premenstrual dysphoric disorder (PMDD) - the most debilitating form of premenstrual syndrome (PMS). 9 July 2018
When Seattle Genetics announced it had bought exclusive global rights to an an exciting new antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), shares in the candidate’s developer shot up by a third. 9 July 2018
The UK’s leading pharmaceutical trade body, the Association of the British Pharmaceutical Industry (ABPI), has appointed Pfizer UK’s managing director Erik Nordkamp as president. 6 July 2018
Guy Payette, president of Innomar Strategies and a former director at Boehringer Ingelheim, has more than 30 years experience in navigating the Canadian healthcare system. In an Expert View piece, he gives his insight on how to bring a product to commercialisation in the Canadian market. 5 July 2018
The Russian government is considering 100% funding of state purchases of drugs against rare and orphan diseases, reports The Pharma Letter’s local correspondent. 5 July 2018
Since it first received US approval for thyroid cancer in February 2015, excitement around Eisai’s Lenvima (lenvatinib mesylate) as one of the hottest properties in oncology has steadily been growing. 4 July 2018
Chugai Pharma Europe, a wholly-owned subsidiary of Chugai Pharmaceutical and its majority owner Roche, has announced the hiring of Troy Robinson as managing director of its UK operations. 3 July 2018
Danish CNS specialist Lundbeck has appointed Dr Deborah Dunsire as new president and CEO of Lundbeck. Dr Dunsire will take up her new position on September 1, 2018. 2 July 2018
Pharma companies sometimes need to be aware of advances in wearable technology that threaten to take market share away from their medicines, but such devices can also work well when used in conjunction with drugs. 2 July 2018
Synthetic biology — a discipline derived from the convergence of biotechnology, genetic engineering, systems biology and more — is ready for its time in the sun. 2 July 2018
In an Expert View piece, Andreas von Falck and Miriam Gundt, both partners at Hogan Lovells' global patent litigation practice, give an overview of the intellectual property landscape for drugmakers in Europe. 28 June 2018
In a major restructuring, privately-held Switzerland-based healthcare company Roivant Sciences has created two new business units, Roivant Pharma and Roivant Health, to focus its efforts on accelerating the launch of new innovative healthcare companies, including ‘Vants’ oriented around earlier-stage scientific platforms. 28 June 2018
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024